title: Epistaxis and severe weakness in a patient with multiple myeloma. Therapy-related acute myeloid leukemia, pure erythroid leukemia.
abstract: Therapy-related acute myeloid leukemias arise as a result of cytotoxic chemotherapy and/or radiation therapy. The most common types of acute myeloid leukemia arising in this setting are acute myeloid leukemia with maturation, and lesser numbers of acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, or acute megakaryocytic leukemia. We present a patient with multiple myeloma who was treated with melphalan and 4 years later developed acute erythroid leukemia. The morphologic diagnosis of pure erythroid leukemia developing in the setting of multiple myeloma may be challenging.
authors.affiliation: Department of Pathology, New York University Medical Center, New York 10016, USA.
authors.forename: Chuanhai
authors.initials: C
authors.lastname: Guo
authors.forename: Giorgio
authors.initials: G
authors.lastname: Inghirami
authors.forename: Sherif
authors.initials: S
authors.lastname: Ibrahim
authors.forename: Filiz
authors.initials: F
authors.lastname: Sen
mesh_terms: D000208:Acute Disease; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D004844:Epistaxis / Q000150:complications*; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000139:chemically induced / Q000150:complications* / Q000473:pathology; D007951:Leukemia, Myeloid; D008297:Male; D008558:Melphalan / Q000009:adverse effects; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D018908:Muscle Weakness / Q000150:complications*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan